Biologics News

WAILEA, Hawaii — Orthobiologics offer a faster track in hip fracture healing and show great promise for the future, according to a presenter, here.

Placing leukocyte- and platelet-rich fibrin between the tendon and the bone during arthroscopic rotator cuff repair was linked to a higher vascularization response at 6 weeks compared to repair without the biologic, according to the results of this pilot study.

ISTO Technologies Inc. has named George W. Dunbar, Jr. as president and chief executive officer and the company appointed James McGorry to its board of directors.

Cell differentiation and interleukin-1β expression influenced clinical outcomes up to 5 years after matrix-associated chondrocyte transplantation, according to a recently published study.

Patients who undergo lumbar fusion procedures with an allogenic morphogenetic protein have higher fusion rates in comparison to patients who undergo the same procedures with recombinant human bone morphogenetic protein, according to recently published data.

Periprosthetic joint infections pose a constant challenge to orthopaedic surgeons, many of whom are interested in new research into ways to reduce bacterial colonization.

BioLife Solutions Inc. announced that Discgenics Inc. has incorporated its CryoStor clinical grade cryopreservation freeze media in the development and potential commercialization of their Injectable Discogenic Cell Therapy product to treat patients with low back pain associated with degenerative disc disease.

Patients with spondylarthritis who were treated with anti-tumor necrosis factor tended to have greater incidence of malignancy when compared with the rate among the Belgian population, according to recent study results.

Researchers of a study which outlined the evidence-based uses of platelet-rich plasma found that the therapy is efficacious in the treatment of lateral epicondylitis, but other indications require additional research.

The FDA elected to provide independent review on Wright Medical’s Augment Bone Graft and FzioMed’s Oxiplex Gel, both of which received not approvable letters earlier this year.